Jefferies assumed coverage of Fate Therapeutics with a Buy rating and $4 price target. Lead program FAT819 is in Phase 1 for various autoimmune diseases, notes the analyst, who sees the program having potential to effectively treat refractory moderate to severe lupus nephritis and extrarenal lupus in a convenient, on-demand, outpatient setting, the analyst tells investors.
